ANGLE plc (GB:CLBX)
LSE:CLBX
Top Page
ANGLE plc
(LSE:CLBX)
Select Model
Select Model
Rating:48Neutral
Price Target:
0.89 p
Action:UpgradedDate:12/07/25
The overall stock score reflects significant financial challenges and bearish technical indicators, which are the most impactful factors. While recent corporate events and earnings call achievements provide some positive outlook, the financial and valuation concerns weigh heavily on the score.
Positive Factors
Strategic partnerships enabling commercialization
A large medtech collaboration with Myriad Genetics creates durable commercial distribution capabilities and scales go-to-market reach for Parsortix. This structural partnership can accelerate adoption, provide commercialization expertise, and open payer and clinical channels beyond one-off research sales.
Negative Factors
Limited cash runway
A cash runway ending in Q1 2026 creates a structural financing risk that can force dilutive capital raises or constrain strategic investments. Management time and resources may be diverted to fundraising, slowing commercialization and accreditation execution over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic partnerships enabling commercialization
A large medtech collaboration with Myriad Genetics creates durable commercial distribution capabilities and scales go-to-market reach for Parsortix. This structural partnership can accelerate adoption, provide commercialization expertise, and open payer and clinical channels beyond one-off research sales.
Read all positive factors
ANGLE plc (CLBX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£10.80M
Dividend YieldN/A
Average Volume (3M)3.14M
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth29.64%
EPS Growth28.51%
CountryUK
Employees119
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.03
Shares Outstanding1,136,402,700
10 Day Avg. Volume4,374,015
30 Day Avg. Volume3,143,840
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.64
Price to Sales (P/S)10.56
P/FCF Ratio-2.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£3.49M
ANGLE plc Business Overview & Revenue Model
Company Description
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of int...
How the Company Makes Money
ANGLE generates revenue primarily through the sale of its Parsortix systems and related consumables. The company also earns income from service contracts and collaborations with research institutions and pharmaceutical companies that utilize its t...
ANGLE plc Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.62M | 2.86M | 2.19M | 1.04M | 1.01M | 762.00K |
| Gross Profit | 1.63M | 1.78M | -408.00K | 613.00K | 711.00K | 597.00K |
| EBITDA | -15.60M | -13.02M | -19.48M | -22.06M | -15.74M | -12.29M |
| Net Income | -15.78M | -14.22M | -20.13M | -21.69M | -15.01M | -11.61M |
Balance Sheet | ||||||
| Total Assets | 18.08M | 25.46M | 31.18M | 49.87M | 47.31M | 39.05M |
| Cash, Cash Equivalents and Short-Term Investments | 5.27M | 10.43M | 16.22M | 31.90M | 31.84M | 28.62M |
| Total Debt | 3.67M | 4.21M | 4.55M | 5.00M | 2.34M | 1.36M |
| Total Liabilities | 6.39M | 7.02M | 8.24M | 9.80M | 6.99M | 4.71M |
| Stockholders Equity | 11.69M | 18.44M | 22.94M | 40.06M | 40.33M | 34.34M |
Cash Flow | ||||||
| Free Cash Flow | -11.62M | -13.89M | -15.12M | -17.94M | -15.80M | -8.35M |
| Operating Cash Flow | -11.25M | -13.45M | -14.46M | -16.05M | -14.01M | -7.85M |
| Investing Cash Flow | -491.50K | -48.00K | -203.00K | -1.75M | 14.77M | -1.97M |
| Financing Cash Flow | -2.05M | 7.67M | -1.13M | 18.10M | 18.99M | 18.14M |
ANGLE plc Technical Analysis
―
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CLBX, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for GB:CLBX.
ANGLE plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | £7.95M | -0.39 | -122.54% | ― | -57.03% | -15.71% | |
57 Neutral | £123.08M | -5.17 | -3.95% | ― | 31.83% | 46.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | £10.80M | -1.31 | -104.73% | ― | 29.64% | 28.51% | |
47 Neutral | £17.34M | -1.51 | -153.92% | ― | 90.42% | 79.21% | |
45 Neutral | £18.20M | -2.69 | -58.27% | ― | 37.39% | -126.19% | |
42 Neutral | £5.63M | -1.05 | 44.15% | ― | 12.19% | 18.12% |
* Healthcare Sector Average
GB:CLBX
ANGLE plc
0.95
-8.30
-89.73%
GB:GDR
Genedrive
1.08
-0.72
-40.10%
GB:PRM
Proteome Sciences
1.61
-2.45
-60.47%
GB:DXRX
Diaceutics
145.50
19.50
15.48%
GB:VRCI
Verici Dx Plc
0.53
-2.23
-80.91%
GB:ABDX
Abingdon Health PLC
7.25
0.83
12.93%
ANGLE plc Corporate Events
Business Operations and StrategyDelistings and Listing ChangesFinancial Disclosures
CelLBxHealth Tightens Costs and Reshapes Strategy as 2025 Revenues Miss Target
Negative
Jan 16, 2026
CelLBxHealth reported preliminary unaudited 2025 revenues of about £1.4 million, slightly below expectations after roughly £0.2 million of anticipated sales slipped into the first quarter of 2026, while year-end cash stood at £7.3 m...
Business Operations and StrategyExecutive/Board Changes
CelLBxHealth refreshes board and appoints new CEO to drive CTC growth strategy
Positive
Jan 12, 2026
CelLBxHealth plc has strengthened its board with the immediate appointment of Peter Collins as chief executive officer and Klaas de Boer, Kim Oreskovic and Benjamin Hart as non-executive directors, while non-executive director Joseph Eid will step...
Business Operations and StrategyPrivate Placements and Financing
CelLBxHealth Executives and ESOT Boost Holdings After Oversubscribed Placing
Positive
Dec 19, 2025
CelLBxHealth plc has disclosed significant share purchases by its top executives following last month’s oversubscribed placing, with Executive Chairman Jan Groen and CEO Peter Collins each acquiring 5 million shares and Finance Director Sin&...
Executive/Board ChangesDelistings and Listing ChangesShareholder Meetings
CelLBxHealth Announces Board Changes and Share Capital Reorganization
Positive
Dec 15, 2025
CelLBxHealth plc announced that all resolutions were approved at their General Meeting, paving the way for significant changes, including the transition of Peter Collins from Interim CEO to CEO and the anticipated appointment of new board members ...
Private Placements and Financing
CelLBxHealth Secures Additional Investment from Acacia Funds
Positive
Dec 2, 2025
CelLBxHealth plc announced an additional subscription by Conifer Management, LLC, on behalf of the Acacia funds, for 40,891,541 new ordinary shares, raising approximately £0.4 million. This additional subscription, part of a larger fundraisin...
Business Operations and StrategyPrivate Placements and Financing
CelLBxHealth plc Successfully Closes Retail Offer, Raising £0.96 Million
Positive
Dec 1, 2025
CelLBxHealth plc has successfully closed its Retail Offer, raising approximately £0.96 million, with plans to issue 95,869,449 shares at 1.0 pence each, contingent upon the passing of resolutions at an upcoming General Meeting. The company ai...
Delistings and Listing ChangesPrivate Placements and Financing
CelLBxHealth Announces Update on Fundraising Shares Admission
Positive
Nov 25, 2025
CelLBxHealth plc announced an update regarding the admission of fundraising shares following an oversubscribed placing. The first tranche of 9,090,000 shares is expected to be admitted on December 16, 2025, with a second tranche of up to 770,910,0...
Business Operations and StrategyPrivate Placements and Financing
CelLBxHealth plc Completes Oversubscribed Fundraising to Enhance Market Position
Positive
Nov 25, 2025
CelLBxHealth plc has successfully concluded an oversubscribed placing and subscription, raising approximately £6.8 million through the issuance of new shares at a discounted price. This fundraising effort is aimed at expanding the companyR...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
CelLBxHealth Launches Retail Share Offer to Boost Funding
Neutral
Nov 25, 2025
CelLBxHealth plc, a company focusing on healthcare solutions, has announced a retail offer of new ordinary shares at a discounted issue price of 1.0 pence per share. This offer is part of a larger fundraising initiative that includes a conditional...
Business Operations and StrategyPrivate Placements and Financing
CelLBxHealth Announces £6.8 Million Fundraising to Drive Commercial Strategy
Positive
Nov 24, 2025
CelLBxHealth plc has announced a proposed fundraising of £6.8 million through a placing, subscription, and retail offer to support its revised business strategy. The company aims to transition from a research-focused organization to a commerc...
Business Operations and StrategyProduct-Related Announcements
CelLBxHealth Partners with QIAGEN to Enhance CTC-Based Research
Positive
Nov 18, 2025
CelLBxHealth plc has announced a collaboration and co-marketing agreement with QIAGEN Manchester Ltd. to advance CTC-based research. This partnership will combine CelLBxHealth’s Parsortix platform with QIAGEN’s molecular technologies t...
Business Operations and StrategyPrivate Placements and Financing
CelLBxHealth plc Announces £6 Million Fundraising Initiative
Neutral
Nov 5, 2025
CelLBxHealth plc has announced its intention to raise approximately £6 million to extend its cash runway into early 2026. The company is in discussions with shareholders and plans to make an offer to retail investors alongside an institutiona...
Business Operations and StrategyProduct-Related Announcements
CelLBxHealth Unveils Promising Study on CTC Integration with Roche’s Diagnostic Platform
Positive
Nov 5, 2025
CelLBxHealth plc has announced a successful proof-of-concept study demonstrating the compatibility of its Parsortix platform with Roche Tissue Diagnostics’ BenchMark ULTRA automated staining system. This study, presented at the World ADC Con...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
CelLBxHealth’s Parsortix® Platform Recognized as Leading Technology in CTC Analysis
Positive
Nov 4, 2025
CelLBxHealth plc announced a major international expert consensus highlighting the clinical relevance of circulating tumor cell (CTC) analysis in cancer management, with the Parsortix® platform identified as a leading next-generation technolo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.